ICON Public FY2025 EPS Estimate Decreased by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Equities research analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of ICON Public in a research note issued on Monday, January 6th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings per share of $13.98 for the year, down from their previous estimate of $14.11. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.81 EPS and FY2027 earnings at $17.82 EPS.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing the consensus estimate of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the previous year, the firm earned $3.10 EPS. The firm’s revenue was down 1.2% on a year-over-year basis.

Several other brokerages have also recently commented on ICLR. Redburn Atlantic initiated coverage on shares of ICON Public in a research note on Monday, October 14th. They issued a “neutral” rating and a $311.00 price objective for the company. Robert W. Baird decreased their price target on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Evercore ISI decreased their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. The Goldman Sachs Group lowered their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Finally, Leerink Partners restated an “outperform” rating and set a $255.00 target price (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $287.00.

ICON Public Trading Up 3.3 %

NASDAQ:ICLR opened at $222.58 on Wednesday. The stock has a market capitalization of $18.36 billion, a price-to-earnings ratio of 24.81, a PEG ratio of 1.54 and a beta of 1.20. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The stock has a fifty day moving average price of $211.60 and a two-hundred day moving average price of $273.51. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34.

Hedge Funds Weigh In On ICON Public

Institutional investors and hedge funds have recently bought and sold shares of the stock. Foyston Gordon & Payne Inc purchased a new position in shares of ICON Public in the 3rd quarter worth $11,672,000. Icon Wealth Advisors LLC raised its holdings in shares of ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after purchasing an additional 11,840 shares during the period. Sara Bay Financial acquired a new position in shares of ICON Public in the 3rd quarter valued at about $1,143,000. Whittier Trust Co. grew its holdings in shares of ICON Public by 12.3% during the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock worth $1,155,000 after purchasing an additional 441 shares during the period. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in ICON Public during the 2nd quarter worth approximately $54,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.